Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole
NCT06261840
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Trichomonas Vaginitis
- Bacterial Vaginitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Tulane University
- Last updated on ClinicalTrials.gov
- May 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 2
- UAB Sexual Health Research Clinic [SHRC] · Birmingham, AL
- University of Alabama at Birmingham [UAB] Gynecology Clinics · Birmingham, AL
Louisiana · 1
- LSU-CrescentCare Sexual Health Center · New Orleans, LA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.